CONGRESOS

Nuestros médicos oncólogos e investigadores expertos del laboratorio son conferenciantes, a la vez que organizadores de muchos de los más importantes seminarios y reuniones científicas por todo el mundo.

Hemos presentado los resultados de nuestras investigaciones sobre las causas del cáncer y tratamientos novedosos se han presentado en los más importantes congresos nacionales e internacionales.

SELECCIONA UN AÑO PARA VER EL
HISTÓRICO DE CONGRESOS

European Respiratory Congress

FECHA06/09/2016

LUGAR DE REALIZACIÓNLondon, UK

Understanding the mechanisms of TKIs: the cycle of inhibition and resistance: STAT3 and YAP-NOTCH signaling rebound as a compensatory response to gefitinib or osimertinib treatment in EGFR mutant lung cancer Rosell R.

Future Horizons in Lung Cancer

FECHA01/09/2016 - 02/10/2016

LUGAR DE REALIZACIÓNLondon, UK

Understanding the mechanisms of immunotherapy in lung cancer Rosell R.

International Symposium on Resolving Cancer Heterogeneity: The way to personalised medicine

FECHA30/06/2016 - 02/07/2016

LUGAR DE REALIZACIÓNVerona, Italy

Future perspectives for treatment strategies in EGFR mutant NSCLC Rosell R, MD, PhD

First Cancer Cell Signaling Pathways Meeting: An In Depth Look at Trends in Poly-Targeted Lung Cancer Therapy

FECHA15/06/2016

LUGAR DE REALIZACIÓNInstitut Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain

Moving forward in cancer Rosell R. MD, PhD

Intratumor heterogeneity in lung adenocarcinoma: Beyond the genes Ramon y Cajal S. MD, PhD

[volver] Co-activation of signal transducer and activator of transcription 3 (STAT3) and YES-associated protein 1 (YAP1) pathway in EGFR mutant non-small-cell lung cancer Karachaliou N. MD, PhD

Cancer stem cells in EGFR mutant NSCLC Codony J. PhD, Codony C. PhD

Annual Meeting, American Society of Clinical Oncology (ASCO)

FECHA03/06/2016 - 07/06/2016

LUGAR DE REALIZACIÓNChicago, USA

Targeting RET in patients with RET-rearranged lung cancers: results from a global registry Oliver Gautschi, Juergen Wolf, Julien Mazieres, Julie Milia, Thomas Filleron, David Paul Carbone, Mark M. Awad, D. Ross Camidge, Benjamin Besse, Byoung Chul Cho, Pasi A. Janne, Florian Cabillic, Jin-Yuan Shih, Michel Van Den Heuvel, Nir Peled, Daniel D. Karp, Rafael Rosell, Mark G. Kris, Alexander E. Drilon, on behalf of the GLORY investigators. Poster #164061

[volver]
Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): phase (ph) 1/2 trial results Corey J. Langer, Scott N. Gettinger, Lyudmila Bazhenova, Ravi Salgia, Kathryn A. Gold, Rafael Rosell, Alice Tsang Shaw, Glen J. Weiss, David J. Dorer, Victor M. Rivera, Frank G. Haluska, David Kerstein, D. Ross Camidge. Poster #164989

Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status Author(s): Scott N. Gettinger, Sen Zhang, J. Graeme Hodgson, Lyudmila Bazhenova, Sjaak Burgers, Dong-Wan Kim, Daniel Shao-Weng Tan, Han A. Koh, James C. M. Ho, Santiago Viteri Ramirez, Alice Tsang Shaw, Glen J. Weiss, Corey J. Langer, Rudolf M. Huber, Myung-Ju Ahn, William G Reichmann, David Kerstein, Victor M. Rivera, D. Ross Camidge. Poster #9060

Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM) Jose Manuel Trigo Perez, Emilie Van Brummelen, Evgeny Levchenko, Manuel Domine, Pilar Garrido Lopez, Hedy L. Kindler, Daniel Morgensztern, Marjorie Glass Zauderer, Johan F. Vansteenkiste, Santiago Viteri Ramirez, Katherine Baker Neblett, Jeffrey Botbyl, Eddie Jose, Adina Zajac, Ionel Mitrica, Robert S. Sikorski, Li Yan. Poster #8557

Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study Jong-Seok Lee, Ji-Youn Han, Myung-Ju Ahn, In-Jae Oh, HyeRyun Kim, Dae Ho Lee, Erin Marie Bertino, Santiago Viteri Ramirez, Nathan A. Pennell, Antoinette J. Wozniak, Joan H. Schiller, Chester Lin, Harold N. Keer, Mohammad Azab, Benjamin Besse, D. Ross Camidge. Poster #9059

Selective CHK1 inhibition as a therapeutic approach in NSCLC, a new option for KRAS mutated patients and squamous cell carcinoma Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan, Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell. Poster #169740

EGFR  mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer Silvia Calabuig-Fariñas, Eloisa Jantus-Lewintre, Clara Mayo-de las Casas, Nuria Jordana-Ariza, Ariadna Balada, Ana Blasco, Miguel Angel Molina-Vila, Rafael Rosell, Carlos Camps. Proceedings #169534